Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $113,555,368 across 6 holdings for the quarter ended 2023-09-30, in a 13F-HR filed 2023-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-23-000142

Period
2023-09-30
Reported value
$114M
Holdings
6
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BIORA THERAPEUTICS INCadded+9,235,281$20M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q3 2023

Share positions as resolved from 13F-HR 0001123292-23-000142, largest first. % of portfolio is the value over $113,555,368, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,694,481 shares; 2023Q2: 1,694,481 shares; 2023Q3: 10,929,762 shares 10,929,762$23.7M20.89%+9,235,281
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,792,114 shares; 2023Q1: 1,792,114 shares; 2023Q2: 1,792,114 shares; 2023Q3: 1,792,114 shares 1,792,114$4.71M4.15%0Timeline
RVLPQRVL PHARMACEUTICALS PLC ORDINAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 14,600,444 shares; 2023Q1: 14,600,444 shares; 2023Q2: 14,600,444 shares; 2023Q3: 14,600,444 shares 14,600,444$1.26M1.11%0Timeline

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
OMEROS CORPOMEROS CORP NOTE 5.250% 2/1principal72,979,000$44.6M+1,000,000
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC NOTE 7.250%12/0principal53,500,000$28M-50,000,000
Omeros CorpOmeros Corp NOTE 6.250%11/1principal11,005,000$11.3M0

Sold out in Q3 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PARATEK PHARMACEUTICALS INCPARATEK PHARMACEUTICALS INC9,000,000$8.85Mprincipal

How Q3 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-23-000142 base2023-11-14acceptance time not in the bulk data set